The FDA has approved the first cancer therapy biosimilar in the United States, a biosimilar to Avastin (bevacizumab) for the treatment of multiple types of cancer, including colorectal, lung, brain, kidney, and cervical cancers.
The FDA has approved the first gene therapy available in the United States, tisagenlecleucel (Kymriah), for the treatment of pediatric and young adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.
A novel high-intensity sequencing approach enabled broad detection of genomic variants in plasma with high rates of concordance with corresponding tumor tissue in patients with metastatic breast, lung, and prostate cancer.
Patients with mucosa-associated lymphoid tissue (MALT) lymphoma had improved event-free survival when treated with chlorambucil plus rituximab compared with either therapy alone.
A study of pediatric acute lymphoblastic leukemia (ALL) has identified IKZF1 as a new ALL predisposition gene that may play a role both in leukemia pathogenesis and treatment responsiveness.
A phase III study of adjuvant girentuximab in patients with high-risk clear cell RCC showed that the drug provided no clinical benefit compared with placebo.
The use of the PD1 inhibitor nivolumab appeared to be feasible and safe in a small study of patients with untreated, stage I–IIIa non–small-cell lung cancer.
Treatment with the anti–PD-1 antibody pembrolizumab was safe and active in a small study of patients with relapsed or refractory classical Hodgkin lymphoma whose disease progressed after treatment with brentuximab vedotin.
CD38 expression was associated with response to daratumumab monotherapy in patients with multiple myeloma.
OPT-822/821 vaccination did not show any improvement in progression-free survival as maintenance therapy compared with placebo for metastatic breast cancer. But in those patients who had an immune response, the vaccine did appear to show activity.